What arthritis and joint pain are
Arthritis is not a single disease but a group of conditions characterised by joint inflammation, pain, stiffness, and progressive structural damage. The two most common forms are osteoarthritis (OA) and rheumatoid arthritis (RA).
Osteoarthritis is the most prevalent form of arthritis in the UK. It involves degeneration of articular cartilage, remodelling of subchondral bone, and low-grade synovial inflammation, most often affecting the knees, hips, hands, and spine. Pain is the dominant symptom, driven by a combination of mechanical, inflammatory, and neuropathic mechanisms. Rheumatoid arthritis is a systemic autoimmune disease in which the immune system attacks the synovial lining of joints, causing persistent inflammation, erosive bone damage, and, if untreated, progressive joint destruction and disability.
Standard treatments differ between OA and RA. OA management includes exercise, weight loss, paracetamol, nonsteroidal anti-inflammatory drugs (NSAIDs), and, in advanced disease, joint replacement. RA treatment centres on disease-modifying antirheumatic drugs (DMARDs) including methotrexate and biologic therapies. In both conditions, pain relief is often incomplete.
Cannabis research on Arthritis and joint pain
No material in the internal library matched the search terms for arthritis, osteoarthritis, rheumatoid arthritis, or joint pain and cannabis. The page is built entirely from PubMed-indexed evidence.
The published medical literature provides a moderate body of evidence, concentrated on CBD in osteoarthritis.
A systematic review and meta-analysis of cannabis extracts for osteoarthritis, published in 2026, assessed both preclinical and human studies. In this human clinical analysis, the review found mixed results: some human studies reported pain reduction, but the evidence was rated as limited by small sample sizes and short follow-up.
A randomised double-blind placebo-controlled trial of CBD for hand osteoarthritis and psoriatic arthritis, published in 2022 with 136 participants, found that CBD did not differ from placebo on pain intensity over 12 weeks in a human clinical study. The authors reported no statistically significant benefit of CBD over placebo for the primary pain endpoint.
A randomised controlled trial of topical CBD for thumb basal joint arthritis, published in 2022 with 64 participants, found that topical CBD did not reduce pain relative to placebo over 8 weeks in a human clinical study.
An open-label feasibility trial of transdermal CBD for hand osteoarthritis, published in 2024 with 15 participants, reported that participants described reduced pain. This was an open-label human study without a placebo control, so it cannot separate a pharmacological effect from expectation or the natural history of fluctuating OA pain.
A cross-sectional comparison study of cannabis use in arthritis, published in 2026, examined health-related quality of life in people with arthritis who used cannabis versus those who did not. In this human observational study, cannabis use was associated with differences in some quality-of-life measures, but the study design cannot establish causation.
Cell and laboratory studies have identified cannabinoid receptors (CB1 and CB2) in synovial tissue. A 2023 study of equine joints found that CB1 and CB2 receptor expression is upregulated in inflamed synovium. A separate 2023 cell culture study found that cannabigerol (CBG) reduced inflammatory markers in rheumatoid arthritis synovial fibroblasts. These are in vitro and animal tissue findings that establish biological plausibility but do not constitute human treatment evidence.
Animal research has demonstrated that cannabinoid receptor agonists reduce pain behaviour and joint inflammation in rat models of osteoarthritis and collagen-induced arthritis. A 2020 study found that tetrahydrocannabinolic acid (THCA) reduced arthritis severity in a mouse model of collagen-induced arthritis. These findings indicate mechanisms worth investigating in humans.
Compounds studied for Arthritis and joint pain
CBD has been tested in human randomised controlled trials for osteoarthritis pain. Two completed RCTs (hand OA and psoriatic arthritis, thumb basal joint arthritis) did not find that CBD reduced pain relative to placebo. Cell and animal studies show that CBD influences inflammatory pathways relevant to arthritis, but this preclinical evidence has not yet translated into positive human trial results.
THC has not been tested in a completed randomised controlled trial specifically for arthritis pain. A 2026 systematic review of cannabis for osteoarthritis noted that most human studies used whole-plant extracts rather than isolated THC, and evidence was limited. The role of THC in arthritis-related pain remains uncertain.
CBG has been studied in cell culture experiments using rheumatoid arthritis synovial fibroblasts, where it reduced inflammatory cytokine production. No human clinical trial of CBG for arthritis has been completed.
Beta-caryophyllene acts as a selective CB2 receptor agonist. Since CB2 receptors are present in synovial tissue and are upregulated during inflammation, there is a plausible mechanistic link between beta-caryophyllene and joint inflammation. Evidence for this link comes from animal and cell studies only.
Myrcene has been studied in animal pain models. Human arthritis trials of myrcene do not exist.
Limonene has demonstrated anti-inflammatory effects in cell and animal studies. No human clinical trial has tested limonene for arthritis pain.
Limits of the evidence for Arthritis and joint pain
The human evidence for cannabinoids in arthritis is concentrated in osteoarthritis, specifically hand OA. Two randomised controlled trials of CBD for OA pain found no benefit over placebo, and a third study was open-label without a control group.
For rheumatoid arthritis, the human clinical trial evidence is absent. The published evidence consists of in vitro studies on synovial fibroblasts and animal models. These are mechanistic and biological plausibility studies; they do not show that any cannabinoid modifies RA disease activity or reduces RA pain in people.
For large-joint OA (hip, knee), the evidence is thinner still. A systematic review noted limited evidence from small studies with short follow-up.
No randomised controlled trial has compared a cannabinoid against standard arthritis treatments such as NSAIDs, intra-articular corticosteroids, or DMARDs. The relative effectiveness, safety, and tolerability are unknown.
The long-term effects of regular cannabinoid use on joint structure, cartilage health, and bone density in people with arthritis have not been studied. Whether cannabinoids affect the progression of structural joint damage in OA or RA is unknown.
Every clinical reference is from PubMed.
Sources
1. Abafita BJ, Singh A, Aitken D, Antony B. Efficacy and safety of cannabis extracts for osteoarthritis: a systematic review and meta-analysis. Pain Research and Management. 2026;2026:3998239. Study record
2. Vela J, Dreyer L, Petersen KK, Arendt-Nielsen L, Duch KS, Amris K, Kristensen LE. Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind, placebo-controlled trial. Pain. 2022;163(6):1206-1214. Study record
3. Heineman JT, Forster GL, Stephens KL, Cottler PS, Timko MP, DeGeorge BR Jr. A randomized controlled trial of topical cannabidiol for the treatment of thumb basal joint arthritis. Journal of Hand Surgery. 2022;47(7):611-619. Study record
4. Andersen NJ, McGuire E, Lacaille D, Savard J, Rahme E, Fortin PR, Da Costa D. Cannabis use in arthritis: impact on health-related quality of life. Complementary Medicine Research. 2026. Study record
5. Lowin T, Tigges-Perez MS, Constant E, Pongratz G. Anti-inflammatory effects of cannabigerol in rheumatoid arthritis synovial fibroblasts and peripheral blood mononuclear cell cultures are partly mediated by TRPA1. International Journal of Molecular Sciences. 2023;24(1):855. Study record
6. Miagkoff L, Girard CA, St-Jean G, Richard H, Beauchamp G, Laverty S. Cannabinoid receptors are expressed in equine synovium and upregulated with synovitis. Equine Veterinary Journal. 2023;55(3):494-505. Study record
- An open-label feasibility trial of transdermal cannabidiol for hand osteoarthritis (open-label feasibility trial, 2024).
